An interventional guide wire or other interventional device is often used in medical procedures that attempt to establish a pathway through a heavily stenosed or chronically occluded vessel. A chronically occluded vessel is referred to as containing a chronic total occlusion or CTO. During these procedures, the guide wire or device can only be of clinical benefit to establish vessel patency if it is advanced distally into the vessel true lumen.
One technique for restoring patency across a CTO involves advancing a guide wire through the intimal layer of the vessel wall and into the subintimal plane or space, where it can be further advanced distally beyond the CTO. Once in this sub-intimal plane beyond the CTO, it becomes difficult to navigate the guide wire or device back through the subintimal tissue layer to re-gain access into the vessel true lumen, sometimes referred to as a “reentry” into the vessel lumen from the sub-intimal space distally of the CTO. The layer of tissue that separates the vessel true lumen from the subintimal plane is typically in the range from 100 to 500 micrometers thick for vessels in the diameter range from 2 mm to 4 mm, and from 100 to 3000 microns thick, in the largest vessels of the body.
A variety of catheters have been proposed for reentry around a CTO. One is described and shown in U.S. Pat. No. 6,231,546. In this system, the re-entry catheter requires the operator to rotate a catheter shaft while observing a radiopaque marker on the catheter shaft to ensure that a side or lateral port is aimed at the true lumen of the blood vessel. Once the marker indicates the correct orientation of the lateral port, a cannula is extended through the lateral port in order to penetrate through the intimal layer of the blood vessel. It is believed that one drawback of this system is the requirement to rotate the catheter to the correct position while under fluoroscopic imaging otherwise an incorrect orientation of the cannula could cause failure to reenter the parent lumen and potentially cause damage to the vessel.
Another system is described and illustrated in US Patent Application Publication 2013/0072957. In this publication, a balloon is used to orient the cannula into the proper orientation for re-entry into the true vessel lumen. To achieve this, the catheter utilizes an asymmetrical catheter lumen for the cannula. It is believed that this system also suffers from a similar drawback in that the lateral port of the cannula must be oriented in the correct direction towards the true lumen while under fluoroscopy. This is to ensure that the cannula does not penetrate away from the true lumen, which could lead to internal hemorrhaging.
Despite the foregoing and other efforts in the prior art, there remains a need for an improved reentry catheter and method for traversing total chronic occlusions.
Disclosed is a reentry catheter for crossing a vascular occlusion. The catheter includes an elongate flexible tubular body, having a proximal end, a distal end and at least one lumen extending there through. A reentry zone on the tubular body includes at least two and preferably at least three or five or more exit apertures in communication with the lumen, the apertures rotationally offset from each other by at least about 15 degrees and aligned in a spiral pattern around the tubular body. In one implementation, three pairs of opposing apertures are provided.
A method of crossing a chronic total occlusion includes the steps of advancing a guidewire from a vascular lumen through the intima, into a subintimal space and distally beyond the occlusion. A reentry catheter is advanced over the guidewire and beyond the occlusion, such that at least one of a plurality of spirally aligned exit ports on the reentry catheter is rotationally aligned with the lumen. The guidewire is advanced through the at least one exit port to cross the intima and reenter the lumen. The reentry catheter may be removed, and a balloon catheter may be advanced over the wire and the balloon expanded in the subintimal space to create a neolumen that permits perfusion across the occlusion. A stent may be expanded in the neolumen to maintain patency across the occlusion.
There is provided, in accordance with another aspect of the present invention, a re-entry catheter for crossing a vascular occlusion. The catheter comprises an elongate flexible tubular body, having a proximal end, a distal end and at least one lumen extending there through. A reentry zone is defined on the tubular body, comprising at least two exit apertures in communication with the lumen, the apertures rotationally offset from each other by at least about 5 degrees, and the reentry zone is positioned within about 20 cm of the distal end of the tubular body.
The re-entry zone may be comprised of at least three apertures, or at least five apertures, arranged in a spiral configuration around the tubular body. At least one aperture may have a noncircular configuration and at least one aperture may have a major axis in parallel to a longitudinal axis of the tubular body, and a minor, transverse axis. At least one aperture has a minor axis diameter of at least about 0.025 mm.
In accordance with another aspect of the present invention, there is provided a method of crossing a chronic total occlusion. The method comprises the steps of advancing a guidewire from a vascular lumen through the intima, into a subintimal space and distally beyond the occlusion. A reentry catheter is advanced over the guidewire and beyond the occlusion, such that at least one of a plurality of exit ports on the reentry catheter is rotationally aligned with the lumen. The guidewire is advanced through the at least one exit port to cross the intima and reenter the lumen.
The method may additionally comprise the step of applying vacuum to the central lumen or secondary lumen to draw adjacent tissue against one or more side ports. Vacuum may also be used to aspirate hematoma or other embolic material into one or more side ports, and/or the distal guidewire opening into the central lumen.
The method may further comprise the step of proximally retracting the catheter, leaving the guidewire extending into the lumen distally of the occlusion. A balloon catheter may be advanced over the wire and the balloon expanded in the subintimal space. A stent may be expanded in the subintimal space to maintain patency of a neolumen that permits perfusion across the occlusion.
In accordance with a further aspect of the present invention, there is provided a reentry catheter for crossing a vascular occlusion, comprising an elongate flexible tubular body, having a proximal end, a distal end and at least one lumen extending there through; and a reentry zone on the tubular body, comprising at least three opposing pairs of side wall exit apertures in communication with the lumen, each opposing pair of apertures rotationally offset from an adjacent opposing pair of apertures.
The reentry catheter may additionally comprise a reinforcing ring surrounding each aperture. The catheter may be provided with six reinforcing rings, one for each aperture, and the reinforcing rings may be connected together by a frame in the side wall which may be in the form of a tubular support. The reinforcing rings may comprise a radiopaque material. The frame may comprise a helical strut extending between a first and second axially spaced apart opposing pairs of side wall exit apertures.
The catheter may further comprise an inflatable balloon on the tubular body, in communication with a second, inflation lumen extending axially through the tubular body. A guidewire lumen may extend axially through the tubular body between a proximal port and a distal port, and the proximal port may be spaced distally apart from the proximal end or at the proximal end of the tubular body. The proximal port is within about 20 cm of the distal end of the tubular body.
There is also provided an intravascular catheter with fluoroscopically visible indicium of rotational orientation. The catheter comprises an elongate flexible tubular body, having a proximal end, a distal end and a tubular side wall defining at least one lumen extending there through; and first and second opposing pairs of radiopaque rings in the side wall, spaced axially apart from each other; wherein a first transverse axis extending through the first pair of rings is rotationally offset from a second transverse axis extending through the second pair of rings.
The intravascular catheter may further comprise an aperture in the side wall through each ring. The catheter may further comprise a frame connecting the rings, which may comprise one or more struts configured to provide a flexible hinge. At least a portion of the frame in between the first and second opposing pairs of rings in one implementation comprises a spring hinge in the form of at least one helical strut.
In accordance with a further aspect of the present invention, there is provided a subassembly for integration into the wall of a catheter. The subassembly comprises a tubular body having a plurality of aperture portions and intervening hinge portions. Each aperture portion includes a first and a second aperture carried on opposing sides of the tubular body. A first axis extending transversely through the tubular body and the first and second apertures of a first aperture portion is rotationally offset from a second axis extending transversely through the tubular body and the first and second apertures of a second aperture portion.
The hinge portion may comprise a helical strut. The aperture portions and intervening hinge portions may be parts of a unitary body which may be laser cut from a tube. Each aperture may be formed within an eyelet separated from an adjacent eyelet by a hinge portion.
An aperture may have a minor axis and a transverse major axis having a length of at least about 150% of the length of the minor axis. The subassembly body may have a wall thickness of no more than about 0.05 inches, and in some implementations no more than about 0.004 inches.
The subassembly may have at least three pairs of opposing apertures with intervening hinge portions between each aperture pair. A first hinge portion may comprise a helical strut having a first pitch and a second hinge portion spaced apart from the first hinge portion by an aperture pair portion, may have a helical strut having a second, different pitch.
Further features and advantages of the invention will become apparent to those of skill in the art from the following description taken together with the associated drawings and claims.
Referring to
The catheters disclosed herein may readily be adapted for use throughout the body wherever it may be desirable to create an extravascular access or a neo lumen, such as to traverse a CTO or otherwise exit and reenter the lumen. For example, catheter shafts in accordance with the present invention may be dimensioned for use throughout the coronary and peripheral vasculature, the gastrointestinal tract, the urethra, ureters, Fallopian tubes and other lumens and potential lumens, as well.
The catheter 10 generally comprises an elongate tubular body 16 extending between a proximal end 12 and a distal functional end 14. The length of the tubular body 16 depends upon the desired application. For example, lengths in the area of from about 120 cm to about 160 cm or more are typical for use in femoral access percutaneous transluminal coronary applications. Intracranial or other applications may call for a different catheter shaft length depending upon the vascular access site, as will be understood in the art.
The proximal end 12 of catheter 10 is additionally provided with a manifold 18 having one or more access ports as is known in the art. Generally, manifold 18 is provided with a guidewire port 20 in an over-the-wire construction, and an optional side port 22 depending upon the desired functionality. Additional access ports may be provided as needed, depending upon the functional capabilities of the catheter. Manifold 18 may be injection molded from any of a variety of medical grade plastics, or formed in accordance with other techniques known in the art.
The tubular body 16 is provided with a reentry zone 40, extending between a proximal exit port 42 and a distal exit port 44, configured to permit exit of a guidewire therethrough. Preferably at least three or five or seven or more exit ports or port pairs are provided, arranged circumferentially offset from each other so that regardless of the rotational orientation of the catheter in the vessel, at least one exit port will be facing the direction of the true vessel lumen. The exit ports may be arranged in a spiral, with axially adjacent ports rotated from each other about the longitudinal axis of the catheter within the range of from about 5 degrees and 90 degrees, preferably between about 10 degrees and 60 degrees, and in some embodiments between about 15 degrees and 35 degrees.
In an axial direction, adjacent ports may be spaced apart by a distance within the range of from about 2 mm to about 4 mm or about 5 mm and about 15 mm. Side ports define a reentry zone 40 having an axial length from the proximal most port 42 to the distal most port 44 of at least about 2 mm and generally less than about 20 mm; in many implementations between about 4 mm and 15 mm. The side ports define a spiral that extends at least about 45 or 90 degrees around the catheter side wall but typically no more than about 360 degrees and in certain embodiments within the range of from about 270 degrees and 450 degrees.
Referring to
The intima layer can thicken considerably over time, occluding the blood flow through the artery. A chronic total occlusion (CTO) is a complete blockage of the artery. The present invention relates to a method to treat a CTO by creating a new lumen in the subintimal space (between the adventitia and intima) in order to allow blood flow in the artery around the occlusion.
Referring to
As seen in more detail in
Once the guidewire 50 has correctly reentered the lumen distally of the CTO, the reentry catheter 10 can be proximally retracted from the subintimal space leaving the guidewire in position via the neo lumen across the CTO. See
Any of a variety of procedures can be accomplished with the guidewire in position across the CTO. For example, referring to
Additional details of the catheter design may be seen with reference to
Alternatively, if the native arterial lumen is in a different orientation relative to the reentry catheter 10, the guide wire can be axially repositioned and rotated to align and exit via a second different exit port to reenter the arterial lumen at a different orientation as seen in
Referring to
Referring to
The major axis 80 is generally longer than the minor axis 82, and may be at least about 150%, or 175% or 200% or more than the length of the minor axis 82. In some implementations of a reentry catheter, the minor axis 82 is within the range of from about 0.012 inches to about 0.20 inches; or about 0.014 inches to about 0.018 inches. The major axis 80 is within the range of from about 0.024 inches to about 0.046 inches, or about 0.030 inches to about 0.042 inches. In one example, the port is about 0.016 by about 0.034 inches in a catheter having an OD of about 0.038 inches. The minor axis of the port may be less than about half of the tubular body OD and over about half of the catheter body ID.
Preferably, the ID of the tubular catheter body is at least about 120% or 150% or 175% or 200% or more of the OD of the GW intended to be used with the catheter. In one implementation, a catheter having an ID of about 0.028 inches is intended for use with a 0.014 inch guide wire. The difference between the diameter of the guide wire and the ID of the catheter is generally at least about 0.005 or about 0.010 or more, to facilitate manipulation of the guidewire and directing the guidewire towards a desired exit port.
In addition, the relatively large space between the guidewire and the ID of the catheter facilitates application of vacuum (e.g., up to about 29″ Hg, or 20 mm Hg) while the guide wire is in position extending through the tubular body, which allows negative pressure applied to the central lumen to produce suction at the exit ports for anchoring the catheter to the adjacent tissue. Anchoring the reentry zone to adjacent tissue may be desirable to stabilize the catheter and facilitate penetration during the step of puncturing tissue with the guidewire to reenter the vessel lumen distally of the obstruction.
The exit ports 46 may be spaced apart axially by a distance within the range of from about 0.05 inches to about 0.25 inches or in some embodiments from about 0.08 inches to about 0.20 inches. Multi-sized ports can be provided, with a first set of guidewire exit ports and a second set of smaller aspiration ports arrayed among the guidewire ports. Multiple sizes of ports may also be utilized for infusion of therapeutic agents.
A variety of port geometries and ramp geometries may be utilized to optimize control over port selection and guidewire exit. Referring to
Deflection of the guidewire may also be facilitated by an intermediate deflection element such a deflection guide 88. See
Referring to
Extending proximally from the support 92 is a kink resistance and torque transmission feature such as a braided tubular sidewall component 186. Braid 186 may be a stainless steel braid having between about 12 and 20 filaments, and in one implementation 16 rectangular filaments having a width that is at least about 3× or 4× the thickness. The braid may overlay a coil layer 188, which in one implementation is a four filar coil of 0.001″ tungsten wire at about 0.008″ pitch. The braid 186 overlaps the proximal end of the support 92, but in the illustrated implementation the distal end of the coil 188 is spaced proximally apart from the proximal end of the support 92.
At least a first eyelet frame 100 comprising an annular strut 102 encircles a guidewire exit port or aperture 104 on a first side of the tubular body 94. In the illustrated embodiment, the first eyelet frame 100 is spaced apart from the proximal end 96 by a first flexible link 106 in the form of an elongated helical strut 108. Proximal end 96 is additionally provided with a plurality of anchors such as at least about four or six or eight or more proximally extending ribs 110, for facilitating attachment to the outer surface of an underlying catheter body component such as a woven or braided reinforcement layer as shown in
A second eyelet frame 112 in the form of a second annular strut 114 defines a second aperture 116. Second eyelet frame 112 is space distally apart from the first eyelet frame 100 by a second flexible link 118 in the form of a second helical strut 120. The total number of apertures in a reentry zone on a particular reentry catheter can be varied depending upon the desired clinical performance, as has been discussed elsewhere here in.
Referring to
As seen in
The support 92 as shown in
Thus, the white “O” will progress along the length of the support from exit port pair to next adjacent exit port pair, as a function of rotational orientation. In this manner, the clinician can determine the rotational orientation of the distal end of the catheter under fluoroscopic visualization by tracking the location of the O and the X's relative to catheter rotation. This facilitates rotational alignment of the catheter relative to the true lumen, and selection of the appropriate exit port for launching the guidewire through the selected port and in the direction of the true lumen.
Referring to
Trackability and pushability are catheter characteristics that rely on the ability for the distal end of the catheter to push through the tortuous anatomy of the cardiac arteries. The consistency of the bending moments throughout the catheter shaft have significant impact on these use characteristics. The illustrated support insert comprises 9 discrete regions, labelled 1-9 in
1. The proximal end is provided with a plurality of engagement structures such as at least two or four or six or more axially extending fingers designed to overlap and intertwine with the braid and coil reinforcement of the shaft
2. First, proximal, single or dual start, first direction such as clockwise spring section. This proximal spring section has the highest relative stiffness to account for the moment arm to the distal end of the catheter and enable the smooth, approximately constant radius curvature under lateral load, as seen in
3. First proximal port. Annular frame is configured to define an oblong port and opposing aperture pair to provide differing visual presentation under fluoroscopy indicative of rotational orientation. Dual exit locations are approximately 180 degrees rotated.
4. 2nd spring region may have a counterclockwise rotation to enhance torque response, and may also have a dual start. As illustrated, the second spring section has 4 revolutions, 0.014″ pitch, 0.0040″ width.
5. The middle port pair 132 is rotated 60 degrees from first port pair 130. All other geometry of the three port pair frame segments are the same.
6. The third spring region may have about 4 revolutions, 0.014″ pitch, 0.0030″ width.
7. The distal port pair 134 is rotated 60 degrees from the middle port pair 132.
8. The fourth spring region may be provided with between about three and 10 and in the illustrated embodiment six dual start revolutions, 0.0105″ pitch, 0.0030″ width
9. The distal end is provided with a plurality of anchors configured for maximum surface area to allow embedded anchoring within the soft tip material to intertwine with the metallic insert and increase tensile strength.
Any of the pitch and width dimensions provided above can be varied by +/−5%, 10% 15%, or 20% depending upon the desired performance.
Reinforcement of the apertures can be accomplished with multiple components that can articulate. Reinforcement may have spring like components for inter-connection. Material may be polymeric or metallic. Material may be radiopaque. Reinforcement will be layered within polymeric tubing to create a laminate structure. Ports may be cut through the braided regions before or after lamination. Multiple materials of construction may be used. Components may be welded together for robustness. Ports can be singulated (discrete components) and positioned in multiple orientations to optimize selection by the guidewire. Material may be polymeric or metallic. Ports can be single sided. Ports can be dual sided as illustrated.
One aspect of the invention involves aspiration via the side ports to secure adjacent tissue. Aspiration can be accomplished via the guidewire exit ports and/or separate aspiration ports.
For example, referring to
Blood aspiration flow rates, pressure may be controlled via an external vacuum source. Vacuum regulators may be provided to control flow rates, and absolute pressures. Guidwire Re-entry port design may also be used to aspirate blood during access into subintimal space. The vacuum source will be able to measure pressure differentials within the device. The vacuum source may be design as a stand-alone system or connected to a lab's vacuum source. Additionally, a pressure pump may be used as a vacuum source. Vacuum can be applied in a multitude of modes that are controlled by surgeon or automated. Pulsatile for effective aspiration of hematoma, pulsatile to allow axial advancement while removing hematoma, high pressure or low pressure pulsatile vacuum can be controlled by an automatic valve that pulses at a discrete or variable frequency
The catheter shaft may be steerable bi-directionally or uni-directionality. The catheter shaft may have the ability to accumulate torque between the handle and the tip. The catheter may have the ability to advance in a way that ‘taps’ to facilitate tracking—axial extension and compression. All of these characteristics are to facilitate tracking through tortuous anatomy and facilitate traversing the subintimal plane.
Referring to
Referring to
Referring to
The first lumen may also be used for aspiration while the second lumen may only be available for a guidewire. It may be desirable to isolate one or more lumens for aspiration, such as shown in
Referring to
The integrated handle may also be connected to a vacuum source (2) for blood aspiration to prevent hematoma as well as assisting with device fixation within the subintimal space. The integrated device may include a vacuum accumulator within the handle that could interact with operator controls.
The integrated handle and one or two or more lumen extending throughout the catheter may also be configured to be compatible with a variety of commonly used tools for CTO crossing procedures, including guidewires, guide liners to increase stiffness for increase pushability, drilling microcatheters to gain access to the subintimal space; dilation balloon catheters; or infusion pumps for delivering therapeutic agents.
Referring to
It may be desirable to coat the outside surface of the guidewire and/or the inside surface of the wall defining the guidewire lumen with a lubricous coating to minimize friction as the catheter 10 is axially moved with respect to the guidewire. A variety of coatings may be utilized, such as Paralene, Teflon, silicone rubber, polyimide-polytetrafluoroethylene composite materials or others known in the art and suitable depending upon the material of the guidewire or inner surface of the tubular wall.
In prior art intravascular catheters, the intended guidewire is normally configured to substantially occupy the guidewire lumen, with a minimal tolerance necessary to avoid excessive friction. For example, a catheter having a 0.018″ ID guidewire lumen might be used with a 0.014″ guidewire. The reentry guidewire of the present invention is preferably substantially smaller than the ID of the complementary lumen. For example, a 0.014″ guidewire may be used with a catheter 10 having a 0.028″ lumen. In general, the guidewire will have a diameter that is no more than about 80%, and preferably no more than about 70% or 60% of the ID of the corresponding lumen. This provides an aspiration flow path in the space between the guidewire and the lumen wall to enable aspiration of blood from the intraluminal space and anchoring of the catheter against adjacent tissue while the guidewire remains in place. For example, with a 0.014″ guidewire present and a maximum vacuum pressure of 20 mmHg, at least about 6 mL/Min, and preferably at least about 8 mL/MIN or at least about 10 mL/min of saline or water or more is aspirated.
The catheters of the present invention may comprise any of a variety of biologically compatible polymeric resins having suitable characteristics when formed into the tubular catheter body segments. Exemplary materials include polyvinyl chloride, polyethers, polyamides, polyethylenes, polyurethanes, copolymers thereof, and the like. Optionally, the tubular body may further comprise other components, such as radiopaque fillers; colorants; reinforcing materials; reinforcement layers, such as braids and helical reinforcement elements; or the like. In particular, the tubular body may be reinforced such as with an embedded coil or one or two or more braided tubular layers in order to enhance its column strength and torqueability while preferably limiting its wall thickness and outside diameter. The tubular body 16 may be produced in accordance with any of a variety of known techniques for manufacturing interventional catheter bodies, such as by extrusion of appropriate biocompatible polymeric materials.
Radiopaque markers may be provided at least at the distal end 25 and the proximal end of the reentry zone 40. One suitable radiopaque marker comprises a metal band which is fully embedded within the catheter wall. Suitable marker bands can be produced from a variety of materials, including platinum, gold, and tungsten/rhenium alloy.
In many applications, the tubular body 16 is provided with an approximately circular cross-sectional configuration having an external diameter within the range of from about 0.025 inches to about 0.065 inches. In accordance with one embodiment of the invention, the proximal section of tubular body 16 has an external diameter of about 0.042 inches (3.2 f) throughout most of its length. Alternatively, a generally oval or flattened cross-sectional configuration can be provided in a distal zone, as well as other noncircular configurations, depending upon the desired performance.
In a catheter intended for peripheral vascular applications, at least the proximal section of body 16 will typically have an outside diameter within the range of from about 0.039 inches to about 0.110 inches. In coronary vascular applications, the proximal section of body 16 will typically have an outside diameter within the range of from about 0.025 inches to about 0.080 inches. The OD of the catheter may taper or step to a smaller diameter or dimension in a distal zone.
Diameters outside of the preferred ranges may also be used, provided that the functional consequences of the diameter are acceptable for the intended purpose of the catheter. For example, the lower limit of the diameter for any portion of tubular body 16 in a given application will be a function of the number of fluid or other functional lumen contained in the catheter, together with the acceptable minimum performance characteristics.
For example, referring to
The proximal zone may have a length within the range of from about 850-1050 mm, and in some implementations from about 925 to about 975 mm. The intermediate zone may have a length within the range of from about 150 mm to about 250 mm, from about 175 mm to about 225 mm, or about 190 mm to about 210 mm. The distal zone may have a length within the range of from about 150 mm to about 250 mm, from about 180 mm to about 230 mm, or about 195 mm to about 220 mm.
Although the present invention has been described in terms of certain preferred embodiments, it may be incorporated into other embodiments by persons of skill in the art in view of the disclosure herein. The scope of the invention is therefore not intended to be limited by the specific embodiments disclosed herein, but is intended to be defined by the full scope of the following claims.
Further variations and additional details of the catheters disclosed herein are disclosed in the attached Appendix, any one or combination of which may be combined with any of the features described above, depending upon the desired performance. The contents of the Appendix are hereby incorporated by reference in their entirety herein.
This application is a continuation of U.S. application Ser. No. 16/838,863, filed Apr. 2, 2020, now U.S. Pat. No. 11,154,312, which claims priority to U.S. Provisional Patent Application No. 62/830,199, filed Apr. 5, 2019, and to U.S. Provisional Patent Application No. 62/907,299, filed Sep. 27, 2019, the entire contents of each of which are incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
1065018 | Barber | Jun 1913 | A |
1383683 | William | Jul 1921 | A |
3394705 | Abramson et al. | Jul 1968 | A |
4771949 | Behr et al. | Sep 1988 | A |
5201723 | Quinn | Apr 1993 | A |
5221256 | Mahurkar | Jun 1993 | A |
5419777 | Hofling | May 1995 | A |
5464395 | Faxon et al. | Nov 1995 | A |
5536261 | Stevens | Jul 1996 | A |
5738649 | Macoviak | Apr 1998 | A |
5769828 | Jonkman | Jun 1998 | A |
5800407 | Eldor | Sep 1998 | A |
5925016 | Chornenky et al. | Jul 1999 | A |
5957901 | Mottola | Sep 1999 | A |
6161543 | Cox | Dec 2000 | A |
6231546 | Milo et al. | May 2001 | B1 |
6480747 | Schmidt | Nov 2002 | B2 |
6514217 | Selmon et al. | Feb 2003 | B1 |
6579311 | Makower | Jun 2003 | B1 |
6605061 | Vantassel et al. | Aug 2003 | B2 |
6709444 | Makower | Mar 2004 | B1 |
6719725 | Milo et al. | Apr 2004 | B2 |
6733489 | Nutting et al. | May 2004 | B2 |
7134438 | Makower et al. | Nov 2006 | B2 |
7191015 | Lamson et al. | Mar 2007 | B2 |
7229429 | Martin et al. | Jun 2007 | B2 |
7344518 | Mcguckin, Jr. et al. | Mar 2008 | B2 |
7396354 | Rychnovsky et al. | Jul 2008 | B2 |
7632241 | Raijman et al. | Dec 2009 | B2 |
7938795 | Difiore et al. | May 2011 | B2 |
8075580 | Makower | Dec 2011 | B2 |
8105259 | Michishita | Jan 2012 | B2 |
8192403 | Pursley | Jun 2012 | B1 |
8202246 | Kugler et al. | Jun 2012 | B2 |
8295947 | Lamson et al. | Oct 2012 | B2 |
8374680 | Thompson | Feb 2013 | B2 |
8512310 | Kugler et al. | Aug 2013 | B2 |
8834448 | Pursley | Sep 2014 | B1 |
8920449 | Wilkinson | Dec 2014 | B2 |
9095648 | Kassab et al. | Aug 2015 | B2 |
9233224 | Pursley | Jan 2016 | B1 |
9259340 | Heuser et al. | Feb 2016 | B2 |
9301774 | O'day | Apr 2016 | B2 |
9486239 | Anderson et al. | Nov 2016 | B2 |
9867530 | Pursley | Jan 2018 | B2 |
9872685 | Kugler et al. | Jan 2018 | B2 |
9878128 | Kugler et al. | Jan 2018 | B2 |
10065018 | Rocha-Singh et al. | Sep 2018 | B2 |
10070877 | Warren | Sep 2018 | B2 |
10117659 | Zhou et al. | Nov 2018 | B2 |
10172632 | Morero et al. | Jan 2019 | B2 |
10226602 | Panian | Mar 2019 | B1 |
10226603 | Panian | Mar 2019 | B1 |
10265206 | Heuser et al. | Apr 2019 | B2 |
10335174 | Wilkinson | Jul 2019 | B2 |
10456252 | Simon et al. | Oct 2019 | B2 |
10456557 | Guala et al. | Oct 2019 | B2 |
10603467 | Alvarez et al. | Mar 2020 | B2 |
10610669 | Rocha-Singh et al. | Apr 2020 | B2 |
10682502 | Panian | Jun 2020 | B2 |
10722252 | Brenizer et al. | Jul 2020 | B2 |
10806474 | Kugler et al. | Oct 2020 | B2 |
10806487 | Kugler et al. | Oct 2020 | B2 |
10857329 | Davies et al. | Dec 2020 | B2 |
10864041 | Urbanski et al. | Dec 2020 | B2 |
10939928 | Kugler et al. | Mar 2021 | B2 |
10980552 | Mustapha | Apr 2021 | B2 |
11033286 | Anderson | Jun 2021 | B2 |
11065002 | Kugler et al. | Jul 2021 | B2 |
11154312 | Nicholson et al. | Oct 2021 | B2 |
11298511 | Kugler et al. | Apr 2022 | B2 |
11369392 | Nicholson et al. | Jun 2022 | B2 |
11602362 | Nicholson et al. | Mar 2023 | B2 |
20010016729 | Divino et al. | Aug 2001 | A1 |
20020103459 | Sparks et al. | Aug 2002 | A1 |
20020169436 | Gurm et al. | Nov 2002 | A1 |
20030045842 | Kawakita | Mar 2003 | A1 |
20040133158 | Keith et al. | Jul 2004 | A1 |
20050154442 | Eidenschink et al. | Jul 2005 | A1 |
20060276749 | Selmon et al. | Dec 2006 | A1 |
20070010840 | Rosenthal et al. | Jan 2007 | A1 |
20080009804 | Rosetti | Jan 2008 | A1 |
20080154172 | Mauch | Jun 2008 | A1 |
20090043372 | Northrop | Feb 2009 | A1 |
20090112153 | Gregersen | Apr 2009 | A1 |
20090177119 | Heidner | Jul 2009 | A1 |
20090192435 | Gregersen | Jul 2009 | A1 |
20100063479 | Merdan | Mar 2010 | A1 |
20100063534 | Kugler | Mar 2010 | A1 |
20100076404 | Ring | Mar 2010 | A1 |
20100191279 | Kassab et al. | Jul 2010 | A1 |
20100286718 | Kassab et al. | Nov 2010 | A1 |
20110054448 | Bourne et al. | Mar 2011 | A1 |
20110144677 | Ward et al. | Jun 2011 | A1 |
20110224666 | Davies et al. | Sep 2011 | A1 |
20120095485 | Cully et al. | Apr 2012 | A1 |
20120179144 | Carleo | Jul 2012 | A1 |
20120184977 | Wolf | Jul 2012 | A1 |
20130006173 | Alvarez et al. | Jan 2013 | A1 |
20130072957 | Anderson | Mar 2013 | A1 |
20130085477 | Deshpande | Apr 2013 | A1 |
20130197353 | Von Oepem | Aug 2013 | A1 |
20130245430 | Selmon | Sep 2013 | A1 |
20130304108 | Weber et al. | Nov 2013 | A1 |
20130317528 | Anderson et al. | Nov 2013 | A1 |
20140074108 | Warren | Mar 2014 | A1 |
20140155862 | Baxter et al. | Jun 2014 | A1 |
20140228876 | Copeta | Aug 2014 | A1 |
20140275983 | Piccagli | Sep 2014 | A1 |
20150112374 | Wilkinson | Apr 2015 | A1 |
20150174371 | Schaeffer et al. | Jun 2015 | A1 |
20160045714 | Zhou et al. | Feb 2016 | A1 |
20160074627 | Cottone | Mar 2016 | A1 |
20170020563 | Anderson et al. | Jan 2017 | A1 |
20170021127 | Manouchehr et al. | Jan 2017 | A1 |
20170100141 | Morera | Apr 2017 | A1 |
20170246427 | Gurley | Aug 2017 | A1 |
20170281909 | Northrop | Oct 2017 | A1 |
20180036021 | Kassab | Feb 2018 | A1 |
20180056045 | Donoghue et al. | Mar 2018 | A1 |
20180056046 | Kiersey et al. | Mar 2018 | A1 |
20180110525 | Kugler et al. | Apr 2018 | A1 |
20180333162 | Saab | Nov 2018 | A1 |
20180369539 | Rocha-Singh et al. | Dec 2018 | A1 |
20190321059 | Takahashi et al. | Oct 2019 | A1 |
20190336727 | Yang et al. | Nov 2019 | A1 |
20190357893 | Weber | Nov 2019 | A1 |
20200015966 | Kiersey et al. | Jan 2020 | A1 |
20200046944 | Cottone | Feb 2020 | A1 |
20200060718 | Patel | Feb 2020 | A1 |
20200078571 | Kirt | Mar 2020 | A1 |
20200129196 | McCaffrey et al. | Apr 2020 | A1 |
20200147347 | Cottone | May 2020 | A1 |
20200191279 | John et al. | Jun 2020 | A1 |
20200230357 | Fitzgerald | Jul 2020 | A1 |
20200246596 | Panian | Aug 2020 | A1 |
20200315639 | Nicholson et al. | Oct 2020 | A1 |
20200330111 | Nicholson et al. | Oct 2020 | A1 |
20200330731 | Nicholson et al. | Oct 2020 | A1 |
20200368496 | Loesener et al. | Nov 2020 | A1 |
20210045757 | Bouasaysy | Feb 2021 | A1 |
20210052321 | Katoh et al. | Feb 2021 | A1 |
20210085937 | Dalvi | Mar 2021 | A1 |
20210153882 | Kugler et al. | May 2021 | A1 |
20210162184 | Lippert | Jun 2021 | A1 |
20210338975 | Cottone | Nov 2021 | A1 |
20210346656 | Lippert | Nov 2021 | A1 |
20220211397 | Nicholson et al. | Jul 2022 | A1 |
20220280244 | Zheng et al. | Sep 2022 | A1 |
20230381452 | Nishigishi | Nov 2023 | A1 |
Number | Date | Country |
---|---|---|
107260252 | Oct 2017 | CN |
19634866 | Mar 1998 | DE |
102018119605 | Feb 2020 | DE |
H10165508 | Jun 1998 | JP |
WO 0134237 | May 2001 | WO |
WO 0170133 | Sep 2001 | WO |
WO 2006046244 | May 2006 | WO |
WO 2008024597 | Feb 2008 | WO |
WO 2009100129 | Aug 2009 | WO |
WO 2012068273 | May 2012 | WO |
WO 2012158152 | Nov 2012 | WO |
WO 2013003757 | Jan 2013 | WO |
WO 2017175531 | Oct 2017 | WO |
WO 2018165277 | Sep 2018 | WO |
WO 2019005903 | Jan 2019 | WO |
WO 2019209798 | Oct 2019 | WO |
WO 2020076833 | Apr 2020 | WO |
WO 2020206101 | Oct 2020 | WO |
WO 2021014316 | Jan 2021 | WO |
WO 2021021368 | Feb 2021 | WO |
WO 2021084460 | May 2021 | WO |
WO 2021084462 | May 2021 | WO |
WO 2021086903 | May 2021 | WO |
WO 2021163635 | Aug 2021 | WO |
Entry |
---|
Response to Office Action filed Jul. 20, 2023, in U.S. Appl. No. 16/838,841. |
Final Office Action mailed Oct. 5, 2022, in U.S. Appl. No. 17/656,974. |
European extended supplementary Search Report mailed Mar. 14, 2023, in EP Application No. 20784940.7. |
European partial Search Report, lack of unity rejection, and search opinion mailed Dec. 9, 2022, in EP Application No. 20784940.7. |
International Search Report for International Application No. PCT/US20/26360 dated Jun. 25, 2020. |
Office Action mailed Apr. 13, 2022, in U.S. Appl. No. 16/838,841. |
Response to Office Action filed Jul. 7, 2022, in U.S. Appl. No. 16/838,841. |
Office Action mailed Jun. 8, 2022, in U.S. Appl. No. 17/656,974. |
Office Action mailed Nov. 9, 2022, in U.S. Appl. No. 16/838,841. |
Amendment After Final filed Jan. 9, 2023,, in U.S. Appl. No. 16/838,841. |
Office Action mailed Apr. 28, 2023, in U.S. Appl. No. 16/838,841. |
Amendment After Final filed Oct. 19, 2022, in U.S. Appl. No. 17/656,974. |
Notice of Allowance mailed Nov. 16, 2022, in U.S. Appl. No. 17/656,974. |
Final Office Action mailed Oct. 31, 2023, in U.S. Appl. No. 16/838,841. |
Amendment After Final filed Jan. 2, 2024, in U.S. Appl. No. 16/838,841. |
Office Action mailed Feb. 27, 2024, in U.S. Appl. No. 16/838,841. |
Number | Date | Country | |
---|---|---|---|
20220110645 A1 | Apr 2022 | US |
Number | Date | Country | |
---|---|---|---|
62907299 | Sep 2019 | US | |
62830199 | Apr 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16838863 | Apr 2020 | US |
Child | 17452118 | US |